Clonotypic composition of the CD4+ T cell response to a vectored retroviral antigen is determined by its speed

Journal of Immunology

Volumn 193, Issue 4, 2014, Pages 1567-1577

  Thorborn, Georgina ^a   Ploquin, Mickaël J ^a,f   Eksmond, Urszula ^a   Pike, Rebecca ^a,g   Bayer, Wibke ^b   Dittmer, Ulf ^b   Hasenkrug, Kim J ^c   Pepper, Marion ^d   Kassiotis, George ^a,e  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f INSTITUT PASTEUR   (France)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; VIRUS ANTIGEN; VIRUS VACCINE; VIRUS VECTOR;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLONOGENESIS; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; IMMUNOLOGICAL MEMORY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; VACCINATION; VIRUS REPLICATION;

ANIMALS; ANTIBODY AFFINITY; ANTIGEN PRESENTATION; ANTIGENS, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CLONAL SELECTION, ANTIGEN-MEDIATED; FRIEND MURINE LEUKEMIA VIRUS; GENE EXPRESSION PROFILING; GENE PRODUCTS, ENV; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, OX40; VIRAL VACCINES;

EID: 84905968707     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400667     Document Type: Article

References (64)

1. Welsh, R. M., L. K. Selin, and E. Szomolanyi-Tsuda. 2004. Immunological memory to viral infections. Annu. Rev. Immunol. 22: 711-743.
2. Zinkernagel, R. M. 2003. On natural and artificial vaccinations. Annu. Rev. Immunol. 21: 515-546.
3. McMichael, A. J., P. Borrow, G. D. Tomaras, N. Goonetilleke, and B. F. Haynes. 2010. The immune response during acute HIV-1 infection: Clues for vaccine development. Nat. Rev. Immunol. 10: 11-23.
4. Kaufmann, S. H., and A. J. McMichael. 2005. Annulling a dangerous liaison: Vaccination strategies against AIDS and tuberculosis. Nat. Med. 11(4, Suppl.): S33-S44.
5. Parks, C. L., L. J. Picker, and C. R. King. 2013. Development of replicationcompetent viral vectors for HIV vaccine delivery. Curr. Opin. HIV AIDS 8: 402-411.
6. Rollier, C. S., A. Reyes-Sandoval, M. G. Cottingham, K. Ewer, and A. V. Hill. 2011. Viral vectors as vaccine platforms: Deployment in sight. Curr. Opin. Immunol. 23: 377-382.
7. Hansen, S. G., M. Piatak, Jr., A. B. Ventura, C. M. Hughes, R. M. Gilbride, J. C. Ford, K. Oswald, R. Shoemaker, Y. Li, M. S. Lewis, et al. 2013. Immune clearance of highly pathogenic SIV infection. Nature 502: 100-104.
8. McElrath, M. J., S. C. De Rosa, Z. Moodie, S. Dubey, L. Kierstead, H. Janes, O. D. Defawe, D. K. Carter, J. Hural, R. Akondy, et al.; Step Study Protocol Team. 2008. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: A case-cohort analysis. Lancet 372: 1894-1905.
9. Buchbinder, S. P., D. V. Mehrotra, A. Duerr, D. W. Fitzgerald, R. Mogg, D. Li, P. B. Gilbert, J. R. Lama, M. Marmor, C. Del Rio, et al.; Step Study Protocol Team. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-ofconcept trial. Lancet 372: 1881-1893.
10. Gras, S., S. R. Burrows, S. J. Turner, A. K. Sewell, J. McCluskey, and J. Rossjohn. 2012. A structural voyage toward an understanding of the MHC-Irestricted immune response: Lessons learned and much to be learned. Immunol. Rev. 250: 61-81.
11. Vingert, B., S. Perez-Patrigeon, P. Jeannin, O. Lambotte, F. Boufassa, F. Lemaître, W. W. Kwok, I. Theodorou, J. F. Delfraissy, J. Thèze, and L. A. Chakrabarti, ANRS EP36 HIV Controllers Study Group. 2010. HIV controller CD4+ T cells respond to minimal amounts of Gag antigen due to high TCR avidity. PLoS Pathog. 6: E1000780.
12. Alexander-Miller, M. A., G. R. Leggatt, and J. A. Berzofsky. 1996. Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 93: 4102-4107.
13. Almeida, J. R., D. A. Price, L. Papagno, Z. A. Arkoub, D. Sauce, E. Bornstein, T. E. Asher, A. Samri, A. Schnuriger, I. Theodorou, et al. 2007. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204: 2473-2485.
14. Gallimore, A., A. Glithero, A. Godkin, A. C. Tissot, A. Plückthun, T. Elliott, H. Hengartner, and R. Zinkernagel. 1998. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J. Exp. Med. 187: 1383-1393.
15. La Gruta, N. L., P. G. Thomas, A. I. Webb, M. A. Dunstone, T. Cukalac, P. C. Doherty, A.W. Purcell, J. Rossjohn, and S. J. Turner. 2008. Epitope-specific TCRb repertoire diversity imparts no functional advantage on the CD8+ T cell response to cognate viral peptides. Proc. Natl. Acad. Sci. USA 105: 2034-2039.
16. Chen, H., Z. M. Ndhlovu, D. Liu, L. C. Porter, J. W. Fang, S. Darko, M. A. Brockman, T. Miura, Z. L. Brumme, A. Schneidewind, et al. 2012. TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat. Immunol. 13: 691-700.
17. Young, G. R., M. J. Ploquin, U. Eksmond, M. Wadwa, J. P. Stoye, and G. Kassiotis. 2012. Negative selection by an endogenous retrovirus promotes a higher-avidity CD4+ T cell response to retroviral infection. PLoS Pathog. 8: E1002709.
18. Turner, S. J., P. C. Doherty, J. McCluskey, and J. Rossjohn. 2006. Structural determinants of T-cell receptor bias in immunity. Nat. Rev. Immunol. 6: 883-894.
19. Malherbe, L., L. Mark, N. Fazilleau, L. J. McHeyzer-Williams, and M. G. McHeyzer-Williams. 2008. Vaccine adjuvants alter TCR-based selection thresholds. Immunity 28: 698-709.
20. Honda, M., R. Wang, W. P. Kong, M. Kanekiyo, W. Akahata, L. Xu, K. Matsuo, K. Natarajan, H. Robinson, T. E. Asher, et al. 2009. Different vaccine vectors delivering the same antigen elicit CD8+ T cell responses with distinct clonotype and epitope specificity. J. Immunol. 183: 2425-2434.
21. Antunes, I., M. Tolaini, A. Kissenpfennig, M. Iwashiro, K. Kuribayashi, B. Malissen, K. Hasenkrug, and G. Kassiotis. 2008. Retrovirus-specificity of regulatory T cells is neither present nor required in preventing retrovirus-induced bone marrow immune pathology. Immunity 29: 782-794.
22. Hasenkrug, K. J., and B. Chesebro. 1997. Immunity to retroviral infection: The Friend virus model. Proc. Natl. Acad. Sci. USA 94: 7811-7816.
23. Ploquin, M. J., U. Eksmond, and G. Kassiotis. 2011. B cells and TCR avidity determine distinct functions of CD4+ T cells in retroviral infection. J. Immunol. 187: 3321-3330.
24. Bayer, W., M. Tenbusch, R. Lietz, L. Johrden, S. Schimmer, K. Uberla, U. Dittmer, and O. Wildner. 2010. Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection. J. Virol. 84: 1967- 1976.
25. Huang, S., W. Hendriks, A. Althage, S. Hemmi, H. Bluethmann, R. Kamijo, J. Vilcek, R. M. Zinkernagel, and M. Aguet. 1993. Immune response in mice that lack the interferon-g receptor. Science 259: 1742-1745.
26. Müller, U., U. Steinhoff, L. F. Reis, S. Hemmi, J. Pavlovic, R. M. Zinkernagel, and M. Aguet. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264: 1918-1921.
27. Rothe, J., W. Lesslauer, H. Lötscher, Y. Lang, P. Koebel, F. Köntgen, A. Althage, R. Zinkernagel, M. Steinmetz, and H. Bluethmann. 1993. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364: 798-802.
28. Klinger, M., J. K. Kim, S. A. Chmura, A. Barczak, D. J. Erle, and N. Killeen. 2009. Thymic OX40 expression discriminates cells undergoing strong responses to selection ligands. J. Immunol. 182: 4581-4589.
29. Fröhlich, A., B. J. Marsland, I. Sonderegger, M. Kurrer, M. R. Hodge, N. L. Harris, and M. Kopf. 2007. IL-21 receptor signaling is integral to the development of Th2 effector responses in vivo. Blood 109: 2023-2031.
30. Mattner, F., J. Magram, J. Ferrante, P. Launois, K. Di Padova, R. Behin, M. K. Gately, J. A. Louis, and G. Alber. 1996. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur. J. Immunol. 26: 1553-1559.
31. Moran, A. E., K. L. Holzapfel, Y. Xing, N. R. Cunningham, J. S. Maltzman, J. Punt, and K. A. Hogquist. 2011. T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse. J. Exp. Med. 208: 1279-1289.
32. Hashimoto, K., S. K. Joshi, and P. A. Koni. 2002. A conditional null allele of the major histocompatibility IA-b chain gene. Genesis 32: 152-153.
33. Caton, M. L., M. R. Smith-Raska, and B. Reizis. 2007. Notch-RBP-J signaling controls the homeostasis of CD8-dendritic cells in the spleen. J. Exp. Med. 204: 1653-1664.
34. Klarnet, J. P., D. E. Kern, K. Okuno, C. Holt, F. Lilly, and P. D. Greenberg. 1989. FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens. J. Exp. Med. 169: 457-467.
35. Bock, M., K. N. Bishop, G. Towers, and J. P. Stoye. 2000. Use of a transient assay for studying the genetic determinants of Fv1 restriction. J. Virol. 74: 7422-7430.
36. Yueh, A., and S. P. Goff. 2003. Phosphorylated serine residues and an argininerich domain of the moloney murine leukemia virus p12 protein are required for early events of viral infection. J. Virol. 77: 1820-1829.
37. Marques, R., I. Antunes, U. Eksmond, J. Stoye, K. Hasenkrug, and G. Kassiotis. 2008. B lymphocyte activation by coinfection prevents immune control of friend virus infection. J. Immunol. 181: 3432-3440.
38. Moon, J. J., H. H. Chu, M. Pepper, S. J. McSorley, S. C. Jameson, R. M. Kedl, and M. K. Jenkins. 2007. Naive CD4+ T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 27: 203-213.
39. Reimand, J., M. Kull, H. Peterson, J. Hansen, and J. Vilo. 2007. g:Profiler: A web-based toolset for functional profiling of gene lists from large-scale experiments. Nucleic Acids Res. 35: W193-W200.
40. Rusinova, I., S. Forster, S. Yu, A. Kannan, M. Masse, H. Cumming, R. Chapman, and P. J. Hertzog. 2013. Interferome v2.0: An updated database of annotated interferon-regulated genes. Nucleic Acids Res. 41: D1040-D1046.
41. Duley, A. K., M. J. Ploquin, U. Eksmond, C. G. Ammann, R. J. Messer, L. Myers, K. J. Hasenkrug, and G. Kassiotis. 2012. Negative impact of IFN-g on early host immune responses to retroviral infection. J. Immunol. 189: 2521-2529.
42. Di Paolo, N. C., E. A. Miao, Y. Iwakura, K. Murali-Krishna, A. Aderem, R. A. Flavell, T. Papayannopoulou, and D. M. Shayakhmetov. 2009. Virus binding to a plasma membrane receptor triggers interleukin-1 a-mediated proinflammatory macrophage response in vivo. Immunity 31: 110-121.
43. Pasparakis, M., S. Kousteni, J. Peschon, and G. Kollias. 2000. Tumor necrosis factor and the p55TNF receptor are required for optimal development of the marginal sinus and for migration of follicular dendritic cell precursors into splenic follicles. Cell. Immunol. 201: 33-41.
44. Pike, R., A. Filby, M. J. Ploquin, U. Eksmond, R. Marques, I. Antunes, K. Hasenkrug, and G. Kassiotis. 2009. Race between retroviral spread and CD4+ T-cell response determines the outcome of acute Friend virus infection. J. Virol. 83: 11211-11222.
45. Dittmer, U., D. M. Brooks, and K. J. Hasenkrug. 1998. Characterization of a liveattenuated retroviral vaccine demonstrates protection via immune mechanisms. J. Virol. 72: 6554-6558.
46. Sanz-Ramos, M., and J. P. Stoye. 2013. Capsid-binding retrovirus restriction factors: Discovery, restriction specificity and implications for the development of novel therapeutics. J. Gen. Virol. 94: 2587-2598.
47. Jenkins, M. K., A. Khoruts, E. Ingulli, D. L. Mueller, S. J. McSorley, R. L. Reinhardt, A. Itano, and K. A. Pape. 2001. In vivo activation of antigenspecific CD4 T cells. Annu. Rev. Immunol. 19: 23-45.
48. Corse, E., R. A. Gottschalk, and J. P. Allison. 2011. Strength of TCR-peptide/MHC interactions and in vivo T cell responses. J. Immunol. 186: 5039-5045.
49. Obst, R., H. M. Van Santen, D. Mathis, and C. Benoist. 2005. Antigen persistence is required throughout the expansion phase of a CD4+ T cell response. J. Exp. Med. 201: 1555-1565.
50. Celli, S., F. Lemaître, and P. Bousso. 2007. Real-time manipulation of T celldendritic cell interactions in vivo reveals the importance of prolonged contacts for CD4+ T cell activation. Immunity 27: 625-634.
51. Yarke, C. A., S. L. Dalheimer, N. Zhang, D. M. Catron, M. K. Jenkins, and D. L. Mueller. 2008. Proliferating CD4+ T cells undergo immediate growth arrest upon cessation of TCR signaling in vivo. J. Immunol. 180: 156-162.
52. Foulds, K. E., and H. Shen. 2006. Clonal competition inhibits the proliferation and differentiation of adoptively transferred TCR transgenic CD4 T cells in response to infection. J. Immunol. 176: 3037-3043.
53. Weaver, J. M., F. A. Chaves, and A. J. Sant. 2009. Abortive activation of CD4 T cell responses during competitive priming in vivo. Proc. Natl. Acad. Sci. USA 106: 8647-8652.
54. Whitmire, J. K., N. Benning, B. Eam, and J. L. Whitton. 2008. Increasing the CD4+ T cell precursor frequency leads to competition for IFN-g thereby degrading memory cell quantity and quality. J. Immunol. 180: 6777-6785
55. Blair, D. A., and L. Lefrançois. 2007. Increased competition for antigen during priming negatively impacts the generation of memory CD4 T cells. Proc. Natl. Acad. Sci. USA 104: 15045-15050.
56. Gett, A. V., F. Sallusto, A. Lanzavecchia, and J. Geginat. 2003. T cell fitness determined by signal strength. Nat. Immunol. 4: 355-360.
57. Malherbe, L., C. Hausl, L. Teyton, and M. G. McHeyzer-Williams. 2004. Clonal selection of helper T cells is determined by an affinity threshold with no further skewing of TCR binding properties. Immunity 21: 669-679.
58. Fassò, M., N. Anandasabapathy, F. Crawford, J. Kappler, C. G. Fathman, and W. M. Ridgway. 2000. T cell receptor (TCR)-mediated repertoire selection and loss of TCR Vb diversity during the initiation of a Cd4+ T cell response in vivo. J. Exp. Med. 192: 1719-1730.
59. Walker, L. S., and D. M. Sansom. 2011. The emerging role of CTLA4 as a cellextrinsic regulator of T cell responses. Nat. Rev. Immunol. 11: 852-863.
60. Vignali, D. A., L. W. Collison, and C. J. Workman. 2008. How regulatory T cells work. Nat. Rev. Immunol. 8: 523-532.
61. Pepper, M., and M. K. Jenkins. 2011. Origins of CD4+ effector and central memory T cells. Nat. Immunol. 12: 467-471.
62. Thorborn, G., G. R. Young, and G. Kassiotis. 2014. Effective T helper cell responses against retroviruses: Are all clonotypes equal? J. Leukoc. Biol. 10.1189/jlb.2RI0613-347R.
63. Browne, E. P., and D. R. Littman. 2009. Myd88 is required for an antibody response to retroviral infection. PLoS Pathog. 5: E1000298.
64. Vanguri, V., C. C. Govern, R. Smith, and E. S. Huseby. 2013. Viral antigen density and confinement time regulate the reactivity pattern of CD4 T-cell responses to vaccinia virus infection. Proc. Natl. Acad. Sci. USA 110: 288-293.